CONTACT ALLERGY TO CORTICOSTEROIDS: NEW CLASSIFICATION

 

 

Contact allergy to corticosteroids is now a well-established phenomenon, and cases from all over the world have been reported in the literature.  The incidence of the reactions observed, however, varies and depends on several factors such as the nature and amount of corticosteroids used in each country, prescription habits, the awareness among the medical profession of the importance of corticosteroid sensitivity, the selection of the patients and their referral to test centers, the routine testing of screening agents for corticosteroid sensitivity as well as of all the corticosteroids used by the patient, and the test and reading methods.

 

Patients with contact allergy to corticosteroids generally present with a chronic dermatitis that is not exacerbated by but fails to respond to corticosteroid therapy.  Indeed, the allergenic and simultaneous anti-inflammatory effects of topical corticosteroids cause a non-specific self-supporting eczematous condition, which is rarely recognized as a potentially iatrogenic sensitivity.

 

Although infrequent relative to the large scale of their use, allergic reactions may also arise to the corticosteroids administered by inhalation in the treatment of rhinitis or bronchial asthma.  Generalized reactions may, of course, also occur after systemic administration (oral, intravenous, or intra-articular).  The lesions may manifest themselves as eczema, exanthema, purpura, urticaria, and so on.

 

In general, corticosteroid-sensitive patients react upon patch testing to several corticosteroids.  This may in part be because most of them have used large numbers of corticosteroids and would thus be vulnerable to concomitant sensitization.  However, irrefutable proof for the existence of cross-reactions is provided by reactions to substances to which the patient has never been exposed.  Studies in this regard can have practical consequences for the identification of screening agents and for advice regarding the topical and systemic corticosteroids the corticosteroid-sensitive patient can safely use.

 

Our earlier studies had led us to suggest four groups of cross-reacting molecules, which, in the light of new findings (to be published elsewhere in detail), have to be subclassified as regards the ester-type corticosteroids (Table 1).

 

Indeed, when testing Group D molecules, contact allergic reactions are frequently observed with substances such as hydrocortisone-17-butyrate, -aceponate and -butyrate, as well as methylprednisolone aceponate and prednicarbate than with molecules such as betamethasone and its esters such as valerate and dipropionate, diflucortolone valerate, diflorasone diacetate, clobetasone proprionate, clobetasone butyrate, and also the newer mometasone furoate and fluticasone propionate (now classified as Group D1).  The former esters can be classified as the more sensitizing D2 corticosteroid molecules.  They are "pro-drug" corticosteroids that, because of there high lipophilicity, easily penetrate the skin where they break down into the corresponding structures with the hydroxyl groups at the C21 and/or C17 positions.


As regards the influence of the skin metabolization of corticosteroids, recent patch-test results (data to be published elsewhere in detail) have shown that, for instance, positive reactions to "labile" molecules such as prednicarbate and methylprednisolone aceponate correlate significantly with reactions obtained with Group A corticosteroids (p < 0.01), to which the metabolized prednisolone and methylprednisolone belong.  This mechanism might also account for cross-reactions that have been observed between hydrocortisone and hydrocortisone-17-butyrate (our own data), the latter being able to be converted to hydrocortisone-21-butyrate, which is rapidly hydrolyzed to form hydrocortisone.  However, individual skin-metabolization characteristics certainly influence the cross-sensitivity patterns observed.

 

Thus not only the molecular configuration but also their factors such as the presence of certain substituents, the solubility in the vehicle used, skin penetration, and skin metabolization seem to be critical for the sensitization and cross-sensitization potential of individual corticosteroids.

 

As most contact allergies are missed if corticosteroids are not routinely tested, it is useful to add two or three screening corticosteroids to the standard series: tixocortol pivalate (0.1 % pet.), budesonide (0.1 % pet.) and sometimes also hydrocortisone-17-butyrate (1 % ethanol).  Should a corticosteroid sensitivity be detected, more extensive corticosteroid series should be tested, if possible, to determine cross-reactivity patterns so that appropriate advice for the future can be given both for local and for systemic corticosteroid therapy.

 

 

Table 1: Classification of corticosteroids in function of cross-reaction patterns

 

Group A

 

-   Characteristics of the group: no methyl substitution on C16, no side chain on C17, possibly short side chain on C21

-   Typical members: cloprednol, fludrocortisone acetate, hydrocortisone, methylprednisolone, prednisolone, tixocortol pivalate

-   Possible cross reactions outside the group with D2 group labile steroids: hydrocortisone aceponate, hydrocortisone-17-butyrate, methylprednisolone aceponate, prednicarbate

 

 

Group B

 

-   Characteristics of the group: Cis diol or ketal function on C16 and C17, possibly a side chain on C21

-   Typical members: budesonide (R- & S-isomer), amcinonide, desonide, fluocinolon acetonide, triamcinolon acetonide

 

 

Group C

 

-   Characteristics of the group: methyl substitution on C16, no side chain on C17, possibly a side chain on C21

-   Typical members: betamethasone, dexamethasone, flumethasone pivalate, halomethasone

 


Group D1

 

-   Characteristics of the group: methyl substitution on C16 (so far halogenation on the basis structure) side chain ester on C17, often on C21 also

-   Typical members: betamethasone dipropionate; betamethasone-17-valerate, clobetasol propionate, fluticasone propionate, mometasone furoate

 

 

Group D2

 

-   Characteristics of the group: no methyl substitution on C16, (up till now no halogenation of the four ring structure), side chain ester on C17, possibly a side chain on C21)

-   Typical members: hydrocortisone aceponate, hydrocortisone buteprate, hydrocortisone-17-butyrate, methylprednisolone aceponate, prednicarbate

-   Possible cross reactions outside the group: budesonide S-isomer, group A corticosteroids

 

 

References

 

1.      Matura M.  Contact allergy for locally applied corticosteroids.  Thesis submitted in fulfillment of the requirements for the Degree of Doctor in Medical Sciences, Leuven, Belgium, 1998.

2.      Goossens A, Matura M.  Contactallergie voor corticosteroïden: recente ontwikkelingen.  Nederlands Tijdschrift voor Dermatologie en Venereologie, 1999, 9:263-265.